| Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287) |
|---|
| 01/25/2001 | CA2379852A1 Method for down-regulating gdf-8 activity |
| 01/25/2001 | CA2379554A1 Benzimidazolone derivatives and their use as phosphodiesterase inhibitors |
| 01/25/2001 | CA2378930A1 Electron transfer proteins |
| 01/25/2001 | CA2378202A1 New compounds |
| 01/25/2001 | CA2378026A1 Novel glycosyl sulfotransferases gst-4.alpha., gst-4.beta., and gst-6 |
| 01/25/2001 | CA2375458A1 Compositions and methods for the treatment of immune related diseases |
| 01/24/2001 | EP1070708A1 Triazole and imidazole derivatives |
| 01/24/2001 | EP0573568B1 Use of nicotinic analogs for treatment of degenerative diseases of the nervous system |
| 01/24/2001 | CN1281432A Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing same |
| 01/23/2001 | US6177550 Process for extraction of a growth factor complex |
| 01/23/2001 | US6177451 For humans; parkinson's, tourelle's, and alzheimer's diseases |
| 01/23/2001 | US6177445 Substituted isoquinolines as ultra short acting neuromuscular blockers |
| 01/18/2001 | WO2001004354A2 Use of ras inhibitors of inhibiting muscle atrophy |
| 01/18/2001 | WO2001004318A2 Myxoma virus genes for immune modulation |
| 01/18/2001 | WO2001004308A1 Human lim domain proteins |
| 01/18/2001 | WO2001004305A2 Human proteins involved in detoxification |
| 01/18/2001 | WO2001004297A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 01/18/2001 | WO2001004122A2 New 2,3-benzodiazepine derivatives |
| 01/18/2001 | WO2001004116A2 Neurotrophic pyrrolidines and piperidines, and related compositions containing them |
| 01/18/2001 | WO2001003743A1 Manipulation of tissue or organ type using the notch pathway |
| 01/18/2001 | WO2001003720A2 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/18/2001 | WO2001003699A1 Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances |
| 01/18/2001 | WO2001003688A2 Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
| 01/18/2001 | DE19932555A1 Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen Drugs with a protective effect against oxidative-toxic and in particular against cardiotoxic substances |
| 01/18/2001 | CA2379149A1 Neurotrophic pyrrolidines and piperidines, and related compositions and methods |
| 01/18/2001 | CA2379133A1 Human proteins involved in detoxification |
| 01/18/2001 | CA2378989A1 Human lim domain proteins |
| 01/18/2001 | CA2378982A1 Methods of inhibiting muscle atrophy |
| 01/18/2001 | CA2378567A1 Novel myxoma genes for immune modulation |
| 01/18/2001 | CA2378465A1 Manipulation of tissue or organ type using the notch pathway |
| 01/18/2001 | CA2378305A1 New 2,3-benzodiazepine derivatives |
| 01/18/2001 | CA2378179A1 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 01/17/2001 | CN1280578A Bis-quaternary ammonium derivatives as neuromuscular relaxants |
| 01/17/2001 | CN1060776C Procell for manufactare of imidazo benzodiazepine derivatives |
| 01/16/2001 | US6174881 Hydroxymethylimidazodiazepines and their esters |
| 01/11/2001 | WO2001002569A2 Human immune response molecules |
| 01/11/2001 | WO2001002552A2 Double transgenic animals as models for neurodegenerative disease |
| 01/11/2001 | WO2001002406A1 Potassium channel blocking agents |
| 01/11/2001 | WO2001002405A1 Quinuclidine derivatives for treatment of neurological disorders |
| 01/11/2001 | WO2001002381A1 Piperazine derivatives as modulators of chemokine receptor activity |
| 01/11/2001 | WO2001002372A1 Cyclized amino acid derivatives |
| 01/11/2001 | WO2001002368A1 N-heterocyclic derivatives with neuronal activity |
| 01/11/2001 | WO2001002366A2 Substituted isoquinoline derivatives and their use as inticonvulsants |
| 01/11/2001 | WO2001002363A2 N-substituted glycine derivatives |
| 01/11/2001 | WO2001002362A1 Azo amino acid derivatives for the treatment of neurological diseases |
| 01/11/2001 | WO2001002361A1 Beta-amino acid derivatives for the treatment of neurological diseases |
| 01/11/2001 | WO2001002358A2 Cyclized amide derivatives for treating or preventing neuronal damage |
| 01/11/2001 | WO2001001988A1 Compounds having cytokine inhibitory activity |
| 01/11/2001 | WO2001001972A2 SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE |
| 01/11/2001 | WO2001001970A2 New uses potassium channel openers, such as the treatment of epilepsy |
| 01/11/2001 | WO2001001963A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 01/11/2001 | WO2001001962A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 01/11/2001 | WO2000061608A3 Low-molecular inhibitors of complement proteases |
| 01/11/2001 | WO2000061189A3 Water-soluble compositions of bioactive lipophilic compounds |
| 01/11/2001 | WO2000054729A3 Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| 01/11/2001 | WO2000048581A3 Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases |
| 01/11/2001 | CA2527931A1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 01/11/2001 | CA2378116A1 Human immune response molecules |
| 01/11/2001 | CA2376495A1 Substituted isoquinoline derivatives and their use as anticonvulsants |
| 01/11/2001 | CA2375157A1 A method for the improvement of transport across adaptable semi-permeable barriers |
| 01/11/2001 | CA2373882A1 Compounds having cytokine inhibitory activity |
| 01/11/2001 | CA2372742A1 Double transgenic animals as models for neurodegenerative disease |
| 01/10/2001 | EP1066833A2 Cryopreserved cells, system for supplying cells on commission, and preventive or remedial method of infections or cancers |
| 01/10/2001 | EP1066042A2 Steroidal saponins for treating alzheimer's disease |
| 01/10/2001 | EP1066033A1 Smilagenin and anzurogenin-d for the treatment of alzheimer's disease |
| 01/09/2001 | US6172096 Administering 4-pyrazolylbenzenesulfonamide derivatives to treat autoimmune diseases |
| 01/04/2001 | WO2001000824A2 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 01/04/2001 | WO2001000660A1 INHIBITORS OF THE INTEGRIN αvβ¿6? |
| 01/04/2001 | WO2001000655A2 Therapeutic peptides derived from subsequences of bpi |
| 01/04/2001 | WO2001000619A1 Novel fluorinated imidazoline benzodioxane, preparation and therapeutic uses thereof |
| 01/04/2001 | WO2001000585A1 Pyrazolidinol compounds |
| 01/04/2001 | WO2001000235A1 Prion protein binding proteins and uses thereof |
| 01/04/2001 | WO2001000229A1 Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 01/04/2001 | WO2000060082A3 Vesicle associated proteins |
| 01/04/2001 | WO2000031095A3 Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 01/04/2001 | CA2377224A1 Inhibitors of the integrin .alpha.v.beta.6 |
| 01/04/2001 | CA2377200A1 Pyrazolidinol compounds |
| 01/04/2001 | CA2377186A1 Novel fluorinated imidazoline benzodioxane, preparation and therapeutic uses thereof |
| 01/04/2001 | CA2376914A1 Prion protein binding proteins and uses thereof |
| 01/04/2001 | CA2369145A1 Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation |
| 01/03/2001 | EP1064284A1 Hypnotic beta-carboline derivatives, process for their preparation and their use as medicinal products |
| 01/03/2001 | EP1064274A1 Benzenesulfonamide derivatives and their use as medicaments |
| 01/03/2001 | EP1064256A1 Bicyclo [2.2.1] heptanes and related compounds |
| 01/03/2001 | EP1064003A1 Neurotrophic properties of ipgs and ipg analogues |
| 01/03/2001 | CN1278823A 1'-[4-[1-(4-Fluorophenyl)-1(H)-indole-3-yl]-1-butyl]-spiro [isobenzofuran-1(3(H),4'-piperidine] hydrohalogenides |
| 01/03/2001 | CN1278806A Aminothiazole inhibitors of cyclin dependent protein kinasses of cells |
| 01/03/2001 | CN1278802A Benzoxazine and Benzothiazine derivatives and their use in pharmaceuticals |
| 01/03/2001 | CN1278733A Viscous compositions containing carbon dioxide |
| 01/03/2001 | CN1060088C Plaster for treating bone, joint, nerve and musde diseases and preparation method thereof |
| 01/02/2001 | US6168933 Nucleotide sequences coding a transport protein; for the classification, diagnosis, prevention, and treatment of defects in cell proliferation, lipid metabolism and transport |
| 01/02/2001 | US6168920 Extracellular adhesive proteins |
| 12/28/2000 | WO2000078953A2 Human transport proteins |
| 12/28/2000 | WO2000078952A2 Human rna metabolism proteins (rmep) |
| 12/28/2000 | WO2000078815A1 ANTI-αvβ3? RECOMBINANT HUMAN ANTIBODIES, NUCLEIC ACIDS ENCODING SAME AND METHODS OF USE |
| 12/28/2000 | WO2000078746A1 Antiviral agents |
| 12/28/2000 | WO2000078742A1 Chroman derivatives against neurological disorders |
| 12/28/2000 | WO2000078736A1 1,4-diazacycloheptane derivatives as neuroprotective agents |
| 12/28/2000 | WO2000078728A1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds |
| 12/28/2000 | WO2000078360A1 Compositions and methods for the treatment or prevention of autoimmune disorders |
| 12/28/2000 | WO2000078338A1 Compositions for promoting passive elongation of vesical smooth muscle |